BrightSpring Health Services, Inc. Common Stock
BTSG
$58.36
-0.88%
BrightSpring Health Services is a home- and community-based healthcare platform that delivers complementary pharmacy and provider services to complex, high-acuity patients across Medicare, Medicaid, and commercially insured populations, with the Pharmacy Solutions segment generating the majority of revenue. The company occupies a distinctive position as an integrated 'pharmacy-plus-provider' platform serving underserved, poly-chronic patient cohorts — a model that is difficult to replicate and creates cross-referral advantages between its specialty pharmacy and home health assets. The current investor narrative centers on the durability of its specialty pharmacy growth (recently running roughly 30% higher year over year) and management's ability to offset a roughly $200 million revenue headwind from Inflation Reduction Act pharmacy reforms through operational efficiencies, while the divestiture of the ResCare Community Living business to Sevita sharpens focus on the core Provider Services franchise. Debate now hinges on whether margin expansion and double-digit revenue growth can be sustained as IRA dynamics and payer mix pressures evolve, with the stock's strong post-IPO performance amplifying scrutiny on execution.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$58.36
Related headlines
Investment Opinion: Should I buy BTSG Today?
Rating: Buy (accumulate on weakness). The thesis is that BTSG is a re-accelerating, operationally levered healthcare platform whose 23% revenue growth and tripling operating income are not yet reflected in a 26.38x forward PE, with the strong-buy consensus and $78.94 average target (31% upside) anchoring the view. The key caveat is that the stock is near the top of its own valuation band, so entry discipline matters.
Supporting evidence is strong: revenue grew 23.05% YoY to $3.873 billion, operating income tripled to $144.59 million (3.73% margin), net income rose to $86.69 million from $28.21 million, and TTM free cash flow of $402.35 million provides a 3.7% FCF yield. On revenue-based measures the stock screens cheap — PS of 0.59x and EV/Sales of 0.99x — while the 26.38x forward PE is reasonable for 23% growth with expanding margins, and the $70 low analyst target still implies 16% upside.
Risks that could invalidate the thesis are a specialty pharmacy growth deceleration below 20%, a larger-than-expected IRA margin hit, and further working capital drag on free cash flow. This Buy would downgrade to Hold if forward PE expands above 32x without matching earnings revisions, or if revenue growth decelerates below 15%; it would upgrade to a higher-conviction Buy if Q3 FCF recovers above $100 million and gross margin holds above 12.7%. Verdict: fairly valued to modestly undervalued relative to growth, but expensive relative to its own late-2025 history.
Sign up to view all
BTSG 12-Month Price Forecast
The forward view is constructive: 23% revenue growth with tripling operating income and a 26.38x forward PE that is reasonable for the growth profile, backed by unanimous strong-buy coverage and a $70 floor on analyst targets. The main constraint is that the stock sits near the top of its post-IPO valuation band after a 79.43% one-year gain, and the July 18% gap shows sentiment can reverse sharply. I would upgrade to high confidence if Q3 shows gross margin above 12.7% and FCF recovering above $100 million, and downgrade to neutral if revenue growth falls below 15% or the multiple expands above 32x forward without matching earnings revisions.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $78.94 and implied upside of +35.3% versus the current price.
Average Target
$78.94
0 analysts
Implied Upside
+35.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $90
Analyst target range
Coverage is deep and uniformly bullish: 17 analysts follow BTSG with a consensus recommendation of 'strong buy' (mean rating of 1.17 on a 1-to-5 scale where 1 is a strong buy), and the average target price of $78.94 implies roughly 31% upside from the current $60.11. The institutional ratings log shows a striking pattern of reiterations rather than initiations — BTIG, KeyBanc, Morgan Stanley, Wells Fargo, UBS, BofA, TD Cowen, and Goldman Sachs have all maintained Buy or Overweight ratings between June and August 2026, with no downgrades in the record. This reflects high conviction among sell-side analysts, though the absence of fresh upgrades suggests the bullish case is already well understood and priced.
The target range of $70.00 to $90.00 is relatively tight — a spread of about 29% around the midpoint — signaling strong consensus rather than divergent views. The $90 high target likely assumes successful offset of the IRA headwind, continued 20%+ revenue growth, and further margin expansion toward the mid-teens gross margin; the $70 low still represents about 16% upside and appears to price in slower specialty pharmacy growth or modest margin compression rather than a bear-case collapse. Notably, the lowest analyst target sits above the current price, meaning even the most cautious coverage implies upside — a rare configuration that underscores how far the stock has pulled back from its July highs relative to fundamental expectations.
Bulls vs Bears: BTSG Investment Factors
The bull case currently has stronger evidence: revenue is accelerating at 23% with operating income tripling, and all 17 analysts rate the stock a strong buy with even the lowest target 16% above the current price. The bear case rests less on deteriorating fundamentals than on valuation and fragility — a 39.84x trailing PE near the top of the post-IPO band, thin 1.48% net margins, and a July gap that proved sentiment can reverse violently. The single most important tension is whether specialty pharmacy growth near 30% and margin expansion can be sustained as the $200 million IRA headwind and payer-mix pressures evolve; if margins hold, the forward PE of 26.38x looks reasonable, but any deceleration would likely trigger multiple compression toward the 24–30x range seen in late 2025.
Bullish
- Revenue re-accelerating to 23% YoY: Q2 2026 revenue of $3.873 billion grew 23.05% year over year versus $3.148 billion in Q2 2025, a sharp inflection from the roughly 9–10% growth seen in mid-2025. The sequential climb from $3.551 billion in Q4 2025 and $3.614 billion in Q1 2026 shows the acceleration is durable, not a one-quarter anomaly.
- Operating leverage driving margin expansion: Operating income more than tripled to $144.59 million (3.73% margin) from $48.56 million (1.54%) a year earlier, while SG&A grew only 6.7% ($348.15 million vs. $326.30 million) against 23% revenue growth. Net income rose to $86.69 million (2.24% margin) from $28.21 million (0.90%), demonstrating that incremental revenue is dropping through to profit.
- Uniformly bullish analyst coverage: All 17 covering analysts rate BTSG a 'strong buy' (mean 1.17), with an average target of $78.94 implying 31% upside from $60.11. Critically, even the lowest target of $70.00 sits 16% above the current price — a rare configuration showing the pullback from July highs has outpaced fundamental expectations.
- Specialty pharmacy growth engine intact: Specialty pharmacy sales are running roughly 30% higher year over year, the primary driver of the revenue acceleration and the core of the bull case. The integrated pharmacy-plus-provider model creates cross-referral advantages that are difficult for competitors to replicate in high-acuity, poly-chronic patient cohorts.
Bearish
- Valuation near top of post-IPO band: The trailing PE has climbed from 24.64x at year-end 2025 to 39.84x now, and price-to-book has risen from 4.07x to 7.01x over the same span. This places BTSG near the top of its own valuation history, leaving little room for disappointment before multiple compression toward the 24–30x PE levels seen as recently as late 2025.
- Thin margins vulnerable to payer mix: Gross margin of 11.76% and net margin of just 1.48% are structurally low given the pharmacy distribution mix, meaning small shifts in payer mix or drug reimbursement can swing earnings disproportionately. The IRA's $200 million revenue headwind is roughly 1.6% of annualized revenue but a far larger share of net income.
- Weak quarterly free cash flow conversion: Q2 2026 operating cash flow of $43.92 million against $29.03 million of capex left only $14.88 million of quarterly FCF, a sharp drop from Q1's $101.40 million due to a $116.76 million working capital drag. TTM FCF of $402.35 million against an $11.02 billion market cap is a modest 3.7% yield.
- High leverage and volatility: Debt-to-equity of 1.44x and interest coverage of roughly 3.9x leave limited cushion, and the company repaid $308.14 million of debt in Q2 while buying back $60 million of stock. With a beta of 1.878, drawdowns can be nearly twice as severe as the index, consistent with the -23.62% max drawdown on record.
BTSG Technical Analysis
BTSG is in a powerful primary uptrend, with a 1-year gain of 79.43% that massively outpaces the S&P 500's 13.13% advance, translating to 66.30 percentage points of relative strength over twelve months. At $60.11, the stock sits roughly 69% of the way through its 52-week range of $30.64 to $73.75 — comfortably in the upper half but not pinned to the highs, which suggests healthy momentum without the extreme overextension that typically precedes sharp reversals. The 56.54% year-to-date gain confirms the trend has been persistent rather than a single spike.
Short-term momentum is constructive but reveals a notable divergence: the stock has rebounded 7.76% over the past month (beating SPY by 8.78 percentage points), yet it remains down 17.56% over three months, underperforming the market by 20.41 points in that window. That three-month weakness traces to the abrupt late-July gap from $72.88 to $59.71 — a roughly 18% single-session drop — followed by a base-building phase in the high-$50s and a fresh October push back above $63 before the current pullback to $60.11. The pattern looks like a post-shock recovery rather than a trend reversal, with the 1-month rebound signaling buyers are re-engaging, though the failure to reclaim the July highs keeps the medium-term picture in repair mode.
Key technical levels are well defined: resistance sits at the 52-week high of $73.75 (with the $72.88 pre-gap close as an immediate ceiling), while support rests near the $55.70–$56.60 shelf established in September, with the 52-week low of $30.64 as the ultimate floor. A breakout above $73.75 would confirm resumption of the primary uptrend and likely trigger momentum-driven buying, whereas a breakdown below $55.70 would signal the July shock was the start of a deeper distribution phase. With a beta of 1.878, BTSG is roughly 88% more volatile than the market — a critical input for position sizing, as it implies drawdowns can be nearly twice as severe as index moves, consistent with the -23.62% max drawdown on record.
Beta
1.88
1.88x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$31-$74
Price range past year
Annual Return
+72.5%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | +3.1% | -0.2% |
| 3m | -15.9% | +5.5% |
| 6m | +21.7% | +7.1% |
| 1y | +72.5% | +12.3% |
| ytd | +52.0% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
Revenue growth is robust and re-accelerating: Q2 2026 revenue of $3.873 billion grew 23.05% year over year versus $3.148 billion in Q2 2025, extending a clear sequential climb from $3.614 billion in Q1 2026 and $3.551 billion in Q4 2025. The trajectory marks a meaningful inflection from the roughly 9–10% growth seen in mid-2025 (Q2 2025 revenue of $3.148 billion vs. $2.878 billion in Q1 2025), and segment data shows Commercial Insurance at $1.1125 billion and Medicaid at $436.6 million as key revenue pillars. This acceleration — driven by specialty pharmacy strength — is the core of the bull case, though the IRA-related $200 million headwind flagged in recent coverage means investors must watch whether headline growth masks underlying payer-mix pressure.
Profitability is improving steadily, albeit from a thin base: Q2 2026 net income reached $86.69 million (a 2.24% net margin) versus just $28.21 million (0.90% margin) a year earlier, while gross margin expanded to 12.72% from 11.91%. Operating income more than tripled year over year to $144.59 million (3.73% operating margin vs. 1.54%), and EBITDA rose to $186.02 million from $90.40 million — a clear demonstration of operating leverage as SG&A growth ($348.15 million vs. $326.30 million) lagged revenue growth by a wide margin. The 11.76% gross margin is structurally low for healthcare services given the pharmacy distribution mix, so the story is about margin expansion off a low base rather than absolute margin leadership.
Balance sheet and cash flow present a more mixed picture: debt-to-equity stands at 1.44x with a current ratio of 1.57x, and TTM free cash flow of $402.35 million against an $11.02 billion market cap implies a modest FCF yield of roughly 3.7%. ROE of 10.17% and ROA of 4.88% are respectable but not exceptional, and Q2 2026 operating cash flow of just $43.92 million against $29.03 million of capex left only $14.88 million of quarterly FCF — a sharp drop from Q1's $101.40 million, reflecting a $116.76 million working capital drag. The company also repurchased $60 million of stock in Q2 while repaying $308.14 million of debt, signaling confidence but leaving less cushion; interest coverage of roughly 3.9x is adequate but not fortress-like.
Quarterly Revenue
$3.9B
2026-06
Revenue YoY Growth
+23.1%
YoY Comparison
Gross Margin
12.7%
Latest Quarter
Free Cash Flow
$402351000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Because BTSG is profitable (net income of $86.69 million in Q2 2026 and positive TTM EPS of $0.025), the PE ratio is the appropriate primary metric. The trailing PE of 39.84x drops to a forward PE of 26.38x — a roughly 34% compression that implies the market expects earnings to grow substantially, consistent with consensus EPS estimates of $5.45 versus the current trailing figure. The PEG ratio of -0.036 is not meaningful given the near-zero trailing EPS base and should be disregarded in favor of the forward multiple.
Against its industry, BTSG screens cheap on revenue-based measures: a PS ratio of 0.59x and EV/Sales of 0.99x are low in absolute terms, reflecting the low-margin pharmacy distribution component of the model, while EV/EBITDA of 22.21x is the more telling figure for a capital-intensive healthcare platform. The forward PE of 26.38x is reasonable for a company growing revenue 23% with expanding margins, suggesting the market is not paying a rich premium relative to the growth profile — a supportive setup if execution continues. The 4.05x price-to-book looks elevated but is distorted by the leveraged capital structure.
Historically, BTSG's valuation has expanded dramatically: the PE ratio has climbed from 24.64x at year-end 2025 to 41.51x in Q2 2026, and price-to-book has risen from 4.07x to 7.01x over the same span, while PS has moved from 2.15x to 3.71x. This places the stock near the top of its own post-IPO valuation band, meaning the market is pricing in optimistic expectations for margin expansion and growth durability. The risk is that any disappointment — particularly around IRA impacts or specialty pharmacy sustainability — could trigger multiple compression toward the 24–30x PE levels seen as recently as late 2025.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 25x~53x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on thin margins and weak cash conversion. Gross margin of 11.76% and net margin of 1.48% mean small reimbursement shifts swing earnings disproportionately, and the $200 million IRA headwind is roughly 1.6% of annualized revenue but a much larger share of profit. Q2 2026 free cash flow collapsed to $14.88 million from $101.40 million in Q1 on a $116.76 million working capital drag, and debt-to-equity of 1.44x with interest coverage near 3.9x leaves limited cushion after $308.14 million of Q2 debt repayment.
Market and competitive risks are dominated by valuation compression. The trailing PE of 39.84x and price-to-book of 7.01x sit near the top of the post-IPO band, versus 24.64x and 4.07x at year-end 2025, so any disappointment could compress the multiple toward 24–30x. Specialty pharmacy growth near 30% faces competitive pressure per recent coverage, and with a beta of 1.878 the stock is roughly 88% more volatile than the market, amplifying sector rotation risk. The July 18% single-session gap from $72.88 to $59.71 shows how quickly the crowded strong-buy consensus can unwind.
In a worst-case scenario, specialty pharmacy growth decelerates, IRA-related payer-mix pressure proves larger than the $200 million flagged, and Q3 earnings miss triggers downgrades from the current unanimous strong-buy consensus. The stock would likely retest the September support shelf of $55.70–$56.60, and a break there could open a path toward the 52-week low of $30.64 — a decline of roughly 49% from $60.11. A more moderate adverse case aligning with the $70 low analyst target still implies upside, but the realistic downside in a sentiment reversal is -7% to the $55.70 support and -49% to the 52-week low, consistent with the -23.62% max drawdown already on record.
FAQ
Ranked by severity: first, valuation compression risk, since the 39.84x trailing PE and 7.01x price-to-book sit near the top of the post-IPO band and could revert toward the 24–30x PE seen in late 2025. Second, margin and payer-mix risk, as 1.48% net margins mean the $200 million IRA headwind can swing earnings disproportionately. Third, cash flow risk, with Q2 2026 FCF of just $14.88 million versus $101.40 million in Q1 due to a $116.76 million working capital drag. Fourth, volatility and sentiment risk, with a 1.878 beta and a demonstrated 18% single-session gap in July showing how quickly the unanimous strong-buy consensus can unwind.
The 12-month forecast has three scenarios: a 30% probability bull case targeting $78.94–$90.00 if specialty pharmacy holds near 30% growth and margins push toward the mid-teens; a 50% probability base case targeting $70.00–$78.94 as growth moderates to the high-teens and the forward PE of 26.38x proves fair; and a 20% probability bear case targeting $55.70–$70.00 if a Q3 earnings miss breaks the strong-buy consensus. The base case is most likely, with the key assumption being that revenue growth decelerates from 23% to roughly 15–18% as the IRA headwind flows through while gross margin holds near 12–13%. Even the bear case range sits at or above the current $60.11 price, reflecting the unusually tight and uniformly bullish analyst target range of $70.00 to $90.00.
The valuation is mixed depending on the metric: the trailing PE of 39.84x looks rich, but the forward PE of 26.38x implies 34% earnings growth and is reasonable for a company growing revenue 23%. On revenue-based measures BTSG screens cheap, with PS of 0.59x and EV/Sales of 0.99x, reflecting the low-margin pharmacy distribution mix, while EV/EBITDA of 22.21x is the more telling figure for a capital-intensive platform. Relative to its own history the stock is expensive — PE has climbed from 24.64x at year-end 2025 and price-to-book from 4.07x to 7.01x — placing it near the top of its post-IPO band. The market is paying a fair price relative to growth but a premium relative to the stock's own recent history, implying it expects margin expansion and specialty pharmacy durability to continue.
From a risk/reward perspective, BTSG offers roughly 31% upside to the $78.94 average analyst target against a realistic downside of about -7% to the $55.70 support shelf and -49% to the 52-week low of $30.64 in a severe scenario. The fundamental momentum is strong — 23.05% revenue growth and operating income tripling — and the 26.38x forward PE is reasonable for that growth. The biggest downside risk is a specialty pharmacy deceleration combined with a larger-than-expected IRA hit, which would compress the multiple from near the top of its post-IPO band. It is a good buy for growth-oriented investors with volatility tolerance, particularly on pullbacks toward the $55.70–$56.60 support, but less suited to conservative or income-focused portfolios given the 1.878 beta and zero dividend.
BTSG is better suited to a medium-to-long-term holding period of at least 12–18 months, given its early growth stage (IPO in January 2024), zero dividend yield, and earnings visibility that is improving but still thin at a 1.48% net margin. The 1.878 beta and -23.62% max drawdown mean short-term trading requires tight risk management, and the July 18% single-session gap shows overnight risk is substantial. Long-term holders can look through quarterly working capital swings and focus on the 23% revenue growth and margin expansion trajectory. A concrete suggested minimum holding period is 12 months, with position sizing that accounts for drawdowns nearly twice the index, and a review triggered if revenue growth falls below 15% or gross margin drops below 11.5%.